CD40 ligation inhibits IL-2 and SAC+IL-2 induced proliferation in chronic lymphocytic leukaemia cells

Scandinavian Journal of Immunology

Volumn 45, Issue 6, 1997, Pages 706-714

  Soderberg O ^a   Christiansen, I ^a   Carlsson, M ^a   Nilsson, K ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CD5 ANTIGEN; INTERLEUKIN 2; INTERLEUKIN 4; MONOCLONAL ANTIBODY; THIOREDOXIN;

ADULT; ARTICLE; B LYMPHOCYTE; CELL CYCLE; CHRONIC LYMPHATIC LEUKEMIA; DNA SYNTHESIS; HUMAN; HUMAN CELL; LYMPHOCYTE PROLIFERATION; NORMAL HUMAN; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

EID: 0030950065     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1997.d01-451.x     Document Type: Article

References (35)

1. Kipps TJ, Duffy SF. Relationship of the CD5 B cell to human tonsillar lymphocytes that express autoantibody-associated cross-reactive idiotypes. J Clin Invest 1991;87:2087-96.
2. Sasso EH, van Dijk KW, Bull AP, Milner E. A fetally expressed immunoglobulin VH1 gene belongs to a set of alleles. J Clin Invest 1993;91:2358-67.
3. Küppers R, Gause A, Rajewsky K. B cells of chronic lymphatic leukemia express V genes in unmutated form. Leuk Res 1991;15:487-96.
4. Schena M, Larsson LG, Gottardi D et al. Growth- and differentiation-associated expression of bcl-2 in B-chronic lymphocytic leukemia cells. Blood 1992;79:2981-9.
5. Nilsson K. The control of growth and differentiation in chronic lymphocytic leukemia (B-CLL) cells. In: Cheson BD, ed. Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments. NY, Basel, Hong Kong: M Dekker Inc., 1992:33-61.
6. Carlsson M, Tötterman TH, Rosén A, Nilsson K. Interleukin-2 and a T cell hybridoma (MP6) derived B cell-simulatory factor acts synergistically to induce proliferation and differentiation of human B-chronic lymphocytic leukemia cells. Leukemia 1989;3:593-601.
7. Smith S, Brown-Galatola CH, Hall ND. Modulation of human T cell functions by surface sulphydryl groups: differential effects on IL-2 production and responsiveness. Clin Exp Immunol 1992;88:169-73.
8. Schenk H, Vogt M, Droge W, Schulze-Osthoff K. Thioredoxin as a potent costimulus of cytokine expression. J Immunol 1996;156:765-71.
9. Iwata S, Hori T, Sato N et al. Thiol-mediated redox regulation of lymphocyte proliferation. J Immunol 1994;152:5633-42.
10. Morris DL, Rothstein TL. CD5+ B(B-1) cells and immunity. In: Snow EC, ed. Handbook of B and T Lymphocytes. San Diego: Academic Press Inc., 1994:421-45.
11. Karray S, Merle-Béral H, Vasquez A, Gerard JP, Debre P, Galanaud. Functional heterogeneity of B-CLL lymphocytes: dissociated responsiveness to growth factors and distinct requirements for a first activation signal. Blood 1987;70:1105-10.
12. Karray S, Vasquez A, Merle-Beral H, Olive D, Debre P, Galanaud P. Synergistic effect of recombinant IL 2 and interferon-gamma on the proliferation of human monoclonal lymphocytes. J Immunol 1987;138:3824-8.
13. Banchereau J, de Paoli P, Vallé A, Garcia E, Roussel F. Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 1991;251:70-2.
14. Clark EA, Ledbetter JA. Activation of human B cells mediated through two distinct cell surface antigens Bp35 and Bp50. Proc Natl Acad Sci USA 1986;83:4494-8.
15. Rousset F, Garcia E, Banchereau J. Cytokine-induced proliferation and immunoglobulin production of human B lymphocytes triggered through their CD40 antigen. J Exp Med 1991;173:705-10.
16. Defrance T, Vanbervliet B, Durand I, Briolay J, Banchereau J. Proliferation and differentiation of human CD5+ and CD5- B cell subsets activated through their antigen receptors or CD40 antigens. Eur J Immunol 1992;22:2831-9.
17. Defrance T, Fluckiger AC, Rossi JF, Rousset F, Banchereau J. In vino activation of B-CLL cells. Leuk Lymphoma 1991:13-19.
18. Fluckiger AC, Rossi JF, Bussel A, Banchereau J, Defrance T. Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors. Blood 1992; 80:3173-81.
19. Crawford DH, Catovsky D. In vitro activation of leukemic B cells by interleukin-4 and antibodies to CD40. Immunology 1993;80:40-4.
20. Fluckiger AC, Garrone P, Durand I, Galizzi JP, Banchereau J. Interleukin 10 (IL-10) upregulates functional high affinity IL-2 receptors on normal and leukemic B lymphocytes. J Exp Med 1993;178:1473-81.
21. Fluckiger A-C, Brière F, Zurawski G, Bridon J-M, Banchereau J. IL-13 has only a subset of IL-4-like activities on B chronic lymphocytic leukaemia cells. Immunology 1994;83:397-403.
22. Funakoshi S, Longo DL, Beckwith M et al. Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood 1994;83:2787-94.
23. Carlsson M, Matsson P, Rosén A, Sundström C, Tötterman TH, Nilsson K. Phorbol ester and B cell-stimulatory factor synergize to induce B-chronic lymphocytic leukemia cells to simultaneous secretion and DNA synthesis. Leukemia 1988;22:734-44.
24. Carlsson M, Sundstöm C, Bengtsson M, Tötterman TH, Rosén A, Nilsson K. Interleukin 4 strongly augments or inhibits DNA synthesis and differation of B-type chronic lymphocytic leukemia cells depending on the co-stimulatory activation and progressing signals. Eur J Immunol 1989;19:913-21.
25. Carlsson M, Söderberg O, Nilsson K. Interleukin-4 (IL-4) enhances homotypic adhesion of activated B-chronic lymphocytic leukemia (B-CLL) cells via a selective upregulation of CD54. Scand J Immunol 1993;37:515-22.
26. Rosén A, Uggla C, Szigeti R, Kallin B, Lindqvist C, Zeuthen J. A T-helper cell x Molt4 human hybridoma constitutively producing B-cell stimulatory and inhibitory factors. Lymphokine Research 1986;5:185-204.
27. Vindelöf L. Flow microfluorometric analysis of nuclear DNA in cells from solid tumors and cell suspensions: a new method for rapid isolation and staining of nuclei. Virchows Arch B cell Pathol 1977; 24:227-42.
28. Rosén A, Lundman P, Carlsson M et al. A CD4+ T cell line-secreted factor, growth promoting for normal and leukemic B cells, identified as thioredoxin. Int Immunol 1995;7:625-33.
29. Nakase K, Kita K, Ueda T, Tanaka I, Shirakawa S, Tsudo M. Differential expression of interleukin-2 receptors (α and β chain) in mature lymphoid neoplasms. Am J Hematol 1994;46:179-83.
30. Tötterman TH, Carlsson M, Simonsson B, Bengtsson M, Nilsson K. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood 1989;74:786-92.
31. Jelinek DF, Lipsky PE. Inhibitory influence of 1L-4 on human B cell responsiveness. J Immunol 1988;141:164-73.
32. Defrance T, Vanbervliet B, Aubry JP, Banchereau J. Interleukin 4 inhibits the proliferation but not the differentiation of activated human B cells in response to interleukin 2. J Exp Med 1988;168:1321-37.
33. Holder MJ, Abbot SD, Milner AE et al. IL-2 expands and maintains IgM plasmoblasts from a CD5+ subset contained within the germinal centre cell-enriched (surface IgD-/CD39-buoyant) fraction of human tonsils. Int Immunol 1993;5:1059-66.
34. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
35. Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206.